Nuzenio

Stabilizes Kidney Function

Stabilizes Kidney Function news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 5 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMT Sibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN - HCPLiveHCPLive · Tue, 04 Aug 2026 15:04:13 GMT Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 14:31:49 GMT Otsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy - TipRanksTipRanks · Mon, 03 Aug 2026 21:56:51 GMT In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 21:00:00 GMT Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business WireBusiness Wire · Mon, 03 Aug 2026 21:00:00 GMT

Timeline

Fri, 07 Aug 2026 12:35:10 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce Pharma

Tue, 04 Aug 2026 15:04:13 GMTSibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN - HCPLive

Tue, 04 Aug 2026 14:31:49 GMTOtsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial - Clinical Trials Arena

Mon, 03 Aug 2026 21:56:51 GMTOtsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy - TipRanks

Mon, 03 Aug 2026 21:00:00 GMTIn a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce Pharma

Mon, 03 Aug 2026 21:00:00 GMTOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy - Business Wire

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Voyxact6 live mentions Otsuka5 live mentions Fierce Pharma Fierce3 live mentions IgAN3 live mentions Clinical Trials Arena3 live mentions Takeda2 live mentions Daiichi2 live mentions Astellas2 live mentions Pharma2 live mentions Phase III IgAN2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Stabilizes Kidney Function.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.